Skip to main content

Advertisement

Fig. 9 | Stem Cell Research & Therapy

Fig. 9

From: Chrysosplenetin promotes osteoblastogenesis of bone marrow stromal cells via Wnt/β-catenin pathway and enhances osteogenesis in estrogen deficiency-induced bone loss

Fig. 9

Chrysosplenetin prevents OVX mouse model from bone loss via promoting osteoblast activity. a Representative images of decalcified bone stained with H&E and immunochemically stained with Bglap on sham mice, OVX mice, and test group treated with 3 mg/kg Chrysosplenetin. Red arrow indicates high expression of Bglap; scale bar: 100 μm; TB, Trabecula. b Quantitative analyses of N.Ob/B.Pm (/mm) (osteoblasts number/bone perimeter) and Ob.S/BS(%) (osteoblast surfaces/bone surface) of mice. Relative Bgalp expression in mouse femurs (n = 6). c Quantitative analyses of Osteocalcin/Bone Gla Protein (Ot/Bgp), Bone Alkaline Phosphatase (Balp), and Calcitonin (Ct) in the serum of mice (n = 6) (*p < 0.05 and **p < 0.01 relative to OVX untreated controls)

Back to article page